The Japanese Daiichi Sankyo has announced that they are preparing to go into Pha
se 1 trials for their mRNA vaccine sometime in late March.
Over in China, there are a handful of companies also working on mRNA vaccines, t
hough they are probably further behind.
Some of the bigger drug makers in China are buying minority stakes in some of th
ese younger start-ups.
However, while the science is known, it requires various building blocks to deve
lop a vaccine.
For mRNA, for example, one key technology is the ability to produce the right ty
pe of fatty lipids to protect the mRNA, and also serve a dual purpose of stimula
ting the deeper and more complex immune response such as trhe production of T ce
lls and neutralising antibodies.
https://bit.ly/3vgDBCg
日本第一三共公司将在3月底
进行一期的mRNA疫苗试验
在中国也有公司在做mRNA疫苗
只是进度比较后面
一些中国的大公司正在买年轻公司的股份
然而，在科学上，需要各种成分研发疫苗
例如mRNA疫苗
关键科技是生产正确的脂肪来保护RNA
还有更复杂的免疫反应
例如T细胞的产生及中和抗体
所以何晶接下来会投资
正在研发mRNA疫苗的公司吗
她的眼光不是一项很好吗！！！
未来会有更多mRNA疫苗！！！